Work Here?
Beeline Medicines
Work Here?
Clinical-stage biotech developing precision autoimmune therapies
Beeline Medicines
Work Here?
Clinical-stage biotech developing precision autoimmune therapies
Overview
Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.
About Beeline Medicines
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$426.3M
Headquarters
Stamford, Connecticut
Founded
2025
People at Beeline Medicines
People at Beeline Medicines who can refer or advise you
Simplify's Take
What believers are saying
- Afimetoran received FDA Fast Track in May 2025, with Phase 2 readout in H2 2026 enabling pivotal program.
- BLN-481 and lomedeucitinib trials will start within 12 months, targeting rare autoimmune conditions with new mechanisms.
- Company secured $426.3M total funding, including $126.3M Series A extension in June 2026, sustaining pipeline advancement.
What critics are saying
- Afimetoran may fail Phase 2 superiority over GSK TLR inhibitors, causing FDA rejection and Fast Track loss in 6–12 months.
- Lomedeucitinib could lose psoriasis proof-of-concept due to off-target JAK activity at high doses, halting rare disease development in 9–15 months.
- BMS may terminate preclinical IL-18/IL-10 biologics license due to missed IND timelines, stripping 40% of pipeline in 12–18 months.
What makes Beeline Medicines unique
- Beeline in-licensed five autoimmune programs from BMS in July 2025, securing a clinically validated pipeline.
- CEO Saqib Islam led SpringWorks to a $1B Merck KGaA buyout in 2025, proving commercialization expertise.
- Afimetoran is equipotent oral TLR7/8 inhibitor, designed for best-in-disease lupus therapy with daily dosing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$426.3M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Health Insurance
Company Equity
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]
Beeline Medicines is Hiring for 33 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Beeline Medicines
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$426.3M
Headquarters
Stamford, Connecticut
Founded
2025
Beeline Medicines is Hiring for 33 Jobs on Simplify!
Find jobs on Simplify and start your career today